{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:26:09Z","timestamp":1762431969028,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10565-020-09565-x","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T14:02:45Z","timestamp":1604066565000},"page":"97-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma"],"prefix":"10.1007","volume":"37","author":[{"given":"Yue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haochuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenguo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-5281","authenticated-orcid":false,"given":"Na","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"3","key":"9565_CR1","first-page":"395","volume":"17","author":"S Abroun","year":"2015","unstructured":"Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F. STATs: an old story, yet mesmerizing. Cell J. 2015;17(3):395\u2013411.","journal-title":"Cell J"},{"issue":"171","key":"9565_CR2","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","volume":"5","author":"JE Allen","year":"2013","unstructured":"Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5(171):171ra17. https:\/\/doi.org\/10.1126\/scitranslmed.3004828.","journal-title":"Sci Transl Med"},{"key":"9565_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-015-0346-9","volume":"14","author":"JE Allen","year":"2015","unstructured":"Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201\/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14:99. https:\/\/doi.org\/10.1186\/s12943-015-0346-9.","journal-title":"Mol Cancer"},{"issue":"4","key":"9565_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.molcel.2018.01.023","volume":"69","author":"G Arena","year":"2018","unstructured":"Arena G, Cisse MY, Pyrdziak S, Chatre L, Riscal R, Fuentes M, et al. Mitochondrial MDM2 regulates respiratory complex I activity independently of p53. Mol Cell. 2018;69(4):594\u2013609 e8. https:\/\/doi.org\/10.1016\/j.molcel.2018.01.023.","journal-title":"Mol Cell"},{"issue":"8","key":"9565_CR5","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","volume":"109","author":"H Avet-Loiseau","year":"2007","unstructured":"Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489\u201395. https:\/\/doi.org\/10.1182\/blood-2006-08-040410.","journal-title":"Blood."},{"issue":"15","key":"9565_CR6","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1158\/0008-5472.CAN-06-1098","volume":"66","author":"LB Baughn","year":"2006","unstructured":"Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4\/6. Cancer Res. 2006;66(15):7661\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1098.","journal-title":"Cancer Res"},{"issue":"2","key":"9565_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89\u2013102. https:\/\/doi.org\/10.1038\/nrc.2017.109.","journal-title":"Nat Rev Cancer"},{"key":"9565_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-981-10-6020-5_12","volume":"1026","author":"Z Cai","year":"2017","unstructured":"Cai Z, Liu Q. Cell cycle regulation in treatment of breast cancer. Adv Exp Med Biol. 2017;1026:251\u201370. https:\/\/doi.org\/10.1007\/978-981-10-6020-5_12.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"9565_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers. 2014;6(2):897\u2013925. https:\/\/doi.org\/10.3390\/cancers6020897.","journal-title":"Cancers."},{"issue":"16","key":"9565_CR10","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","volume":"17","author":"D Chauhan","year":"2011","unstructured":"Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0476.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9565_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/toxsci\/kfs230","volume":"132","author":"L Choucha Snouber","year":"2013","unstructured":"Choucha Snouber L, Bunescu A, Naudot M, Legallais C, Brochot C, Dumas ME, et al. Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and Its active metabolite hydroxyflutamide using HepG2\/C3a microfluidic biochips. Toxicol Sci. 2013;132(1):8\u201320. https:\/\/doi.org\/10.1093\/toxsci\/kfs230.","journal-title":"Toxicol Sci"},{"issue":"1-2","key":"9565_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.18632\/genesandcancer.131","volume":"8","author":"D D\u2019Eliseo","year":"2017","unstructured":"D\u2019Eliseo D, Di Renzo L, Santoni A, Velotti F. Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells. Genes Cancer. 2017;8(1-2):426\u201337. https:\/\/doi.org\/10.18632\/genesandcancer.131.","journal-title":"Genes Cancer"},{"issue":"5","key":"9565_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.clml.2018.03.007","volume":"18","author":"A Dehghanifard","year":"2018","unstructured":"Dehghanifard A, Kaviani S, Abroun S, Mehdizadeh M, Saiedi S, Maali A, et al. Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin lymphoma Myeloma Leuk. 2018;18(5):311\u201320. https:\/\/doi.org\/10.1016\/j.clml.2018.03.007.","journal-title":"Clin lymphoma Myeloma Leuk"},{"issue":"9","key":"9565_CR14","doi-asserted-by":"publisher","first-page":"e0162133","DOI":"10.1371\/journal.pone.0162133","volume":"11","author":"Y Feng","year":"2016","unstructured":"Feng Y, Zhou J, Li Z, Jiang Y, Zhou Y. Small molecular TRAIL inducer ONC201 induces death in lung cancer cells: a preclinical study. PLoS One. 2016;11(9):e0162133. https:\/\/doi.org\/10.1371\/journal.pone.0162133.","journal-title":"PLoS One"},{"issue":"1","key":"9565_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13046-017-0632-z","volume":"36","author":"M Granato","year":"2017","unstructured":"Granato M, Gilardini Montani MS, Santarelli R, D\u2019Orazi G, Faggioni A, Cirone M. Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death. J Exp Clin Cancer Res. 2017;36(1):167. https:\/\/doi.org\/10.1186\/s13046-017-0632-z.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"9565_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1530\/ERC-16-0568","volume":"24","author":"K Jensen","year":"2017","unstructured":"Jensen K, Bikas A, Patel A, Kushchayeva Y, Costello J, McDaniel D, et al. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Endocr Relat Cancer. 2017;24(3):147\u201356. https:\/\/doi.org\/10.1530\/ERC-16-0568.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"9565_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2018.8.","journal-title":"Nat Rev Clin Oncol"},{"key":"9565_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fonc.2018.00665","volume":"8","author":"KK Jovanovic","year":"2018","unstructured":"Jovanovic KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, et al. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2018;8:665. https:\/\/doi.org\/10.3389\/fonc.2018.00665.","journal-title":"Front Oncol"},{"issue":"3","key":"9565_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2141.2009.07752.x","volume":"146","author":"TY Kim","year":"2009","unstructured":"Kim TY, Park J, Oh B, Min HJ, Jeong TS, Lee JH, et al. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br J Haematol. 2009;146(3):270\u201381. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07752.x.","journal-title":"Br J Haematol"},{"key":"9565_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.biopha.2017.09.149","volume":"96","author":"X Li","year":"2017","unstructured":"Li X, Ding R, Han Z, Ma Z, Wang Y. Targeting of cell cycle and let-7a\/STAT3 pathway by niclosamide inhibits proliferation, migration and invasion in oral squamous cell carcinoma cells. Biomed Pharmacother. 2017;96:434\u201342. https:\/\/doi.org\/10.1016\/j.biopha.2017.09.149.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"9565_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153\u201366. https:\/\/doi.org\/10.1038\/nrc2602.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"9565_CR22","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/ncb1109-1275","volume":"11","author":"M Malumbres","year":"2009","unstructured":"Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol. 2009;11(11):1275\u20136. https:\/\/doi.org\/10.1038\/ncb1109-1275.","journal-title":"Nat Cell Biol"},{"issue":"7002","key":"9565_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nature02767","volume":"430","author":"M Mishima","year":"2004","unstructured":"Mishima M, Pavicic V, Gruneberg U, Nigg EA, Glotzer M. Cell cycle regulation of central spindle assembly. Nature. 2004;430(7002):908\u201313. https:\/\/doi.org\/10.1038\/nature02767.","journal-title":"Nature."},{"issue":"2","key":"9565_CR24","first-page":"118","volume":"50","author":"MB Moller","year":"2003","unstructured":"Moller MB. Molecular control of the cell cycle in cancer: biological and clinical aspects. Dan Med Bull. 2003;50(2):118\u201338.","journal-title":"Dan Med Bull"},{"issue":"4","key":"9565_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/annonc\/mdx160","volume":"29","author":"P Musto","year":"2018","unstructured":"Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2018;29(4):1074. https:\/\/doi.org\/10.1093\/annonc\/mdx160.","journal-title":"Ann Oncol"},{"issue":"5","key":"9565_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/13543784.2012.668883","volume":"21","author":"P Neri","year":"2012","unstructured":"Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2012;21(5):733\u201347. https:\/\/doi.org\/10.1517\/13543784.2012.668883.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"9565_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","volume":"113","author":"Y Okawa","year":"2009","unstructured":"Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009;113(4):846\u201355. https:\/\/doi.org\/10.1182\/blood-2008-04-151928.","journal-title":"Blood."},{"issue":"11","key":"9565_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011442.","journal-title":"N Engl J Med"},{"issue":"11","key":"9565_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109. https:\/\/doi.org\/10.1038\/s41408-018-0141-0.","journal-title":"Blood Cancer J"},{"issue":"4","key":"9565_CR30","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1007\/s13277-015-4385-z","volume":"37","author":"LS Silva","year":"2016","unstructured":"Silva LS, Goncalves LG, Silva F, Domingues G, Maximo V, Ferreira J, et al. STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. Tumour Biol. 2016;37(4):5385\u201395. https:\/\/doi.org\/10.1007\/s13277-015-4385-z.","journal-title":"Tumour Biol"},{"issue":"3","key":"9565_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1128\/mcb.24.3.976-984.2004","volume":"24","author":"HK Sluss","year":"2004","unstructured":"Sluss HK, Armata H, Gallant J, Jones SN. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol. 2004;24(3):976\u201384. https:\/\/doi.org\/10.1128\/mcb.24.3.976-984.2004.","journal-title":"Mol Cell Biol"},{"issue":"6647","key":"9565_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/38291","volume":"389","author":"K Somasundaram","year":"1997","unstructured":"Somasundaram K, Zhang HB, Zeng YX, Houvras Y, Peng Y, Zhang HX, et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21(WAF1\/CiP1). Nature. 1997;389(6647):187\u201390.","journal-title":"Nature."},{"issue":"6","key":"9565_CR33","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI96711","volume":"128","author":"J Wagner","year":"2018","unstructured":"Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018;128(6):2325\u201338. https:\/\/doi.org\/10.1172\/JCI96711.","journal-title":"J Clin Invest"},{"issue":"4-5","key":"9565_CR34","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/01902148.2017.1341008","volume":"43","author":"Y Zeng","year":"2017","unstructured":"Zeng Y, Yin B, Wang X, Xia G, Shen Z, Gu W, et al. Effects of the Notch1 signaling pathway on human lung cancer A549 cells. Exp Lung Res. 2017;43(4-5):208\u201316. https:\/\/doi.org\/10.1080\/01902148.2017.1341008.","journal-title":"Exp Lung Res"},{"key":"9565_CR35","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/J.Redox.2019.101392","volume":"29","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhu Q, Bu XM, Zhou YH, Bai DS, Guo QL, et al. Triggering apoptosis by oroxylin A through caspase-8 activation and p62\/SQSTM1 proteolysis. Redox Biol. 2020;29:101392. https:\/\/doi.org\/10.1016\/J.Redox.2019.101392.","journal-title":"Redox Biol"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-020-09565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10565-020-09565-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-020-09565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T08:05:08Z","timestamp":1612166708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10565-020-09565-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["9565"],"URL":"https:\/\/doi.org\/10.1007\/s10565-020-09565-x","relation":{},"ISSN":["0742-2091","1573-6822"],"issn-type":[{"type":"print","value":"0742-2091"},{"type":"electronic","value":"1573-6822"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"13 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved in SPF Animal Laboratory of China Pharmaceutical University. Ethical approval: The present study was approved by the Experimental Animal Ethics Committee of China Pharmaceutical University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}